Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

Compare

117 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIK Analyst Ratings

Moderate Buy

3 Buy

0 Hold

1 Sell

Based on 4 analysts giving stock ratings to

Hikma

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIK Stock 12 Month Forecast

Average Price Target

2,012.50 p

▲(29.50% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is 2,012.50 p with a high forecast of 2,400.00 p and a low forecast of 1,350.00 p. The average price target represents a 29.50% change from the last price of 1,554.00 p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1248":"1,248 p","2401":"2,401 p","1536.25":"1,536.3 p","1824.5":"1,824.5 p","2112.75":"2,112.8 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">2.40K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2012.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">2.01K </span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.35K </span>\n  </div></div>","useHTML":true}}],"tickPositions":[1248,1536.25,1824.5,2112.75,2401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1249,1337.5384615384614,1426.076923076923,1514.6153846153845,1603.1538461538462,1691.6923076923076,1780.230769230769,1868.7692307692307,1957.3076923076924,2045.8461538461538,2134.3846153846152,2222.923076923077,2311.461538461538,{"y":2400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1249,1307.7307692307693,1366.4615384615386,1425.1923076923076,1483.923076923077,1542.6538461538462,1601.3846153846155,1660.1153846153848,1718.8461538461538,1777.576923076923,1836.3076923076924,1895.0384615384614,1953.769230769231,{"y":2012.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1249,1256.7692307692307,1264.5384615384614,1272.3076923076924,1280.076923076923,1287.8461538461538,1295.6153846153845,1303.3846153846155,1311.1538461538462,1318.923076923077,1326.6923076923076,1334.4615384615386,1342.2307692307693,{"y":1350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1871.741,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1928.842,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2218.216,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2090.466,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1919.435,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1969.687,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2116.503,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1962.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1910.567,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1795,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1839,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1550,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1249,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target2,400 p

Average Price Target2,013 p

Lowest Price Target1,350 p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Beatrice Fairbairn

Berenberg Bank

1,800 p→2,300 p

Buy

48.01%

Upside

Assigned

03/04/26

Berenberg Bank Remains a Buy on Hikma Pharmaceuticals (HIK)

Zain Ebrahim

J.P. Morgan

2,000 p

Buy

28.70%

Upside

Reiterated

03/03/26

Hikma Pharmaceuticals (HIK) Receives a Buy from J.P. Morgan

James Gordon CFA

Barclays

1,350 p

Sell

-13.13%

Downside

Reiterated

03/02/26

Barclays Sticks to Their Sell Rating for Hikma Pharmaceuticals (HIK)

Kane Slutzkin

Deutsche Bank

2,500 p→2,400 p

Buy

54.44%

Upside

Reiterated

01/09/26

Deutsche Bank Remains a Buy on Hikma Pharmaceuticals (HIK)

James Vane

Jefferies

2,360 p

Buy

51.87%

Upside

Reiterated

11/07/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Jefferies

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

2,170 p

Buy

39.64%

Upside

Reiterated

11/07/25

Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)

Alistair Campbell

RBC Capital

2,625 p

Buy

68.92%

Upside

Reiterated

08/11/25

Hikma Pharmaceuticals (HIK) Gets a Buy from RBC Capital

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

2,380 p

Hold

53.15%

Upside

Initiated

06/09/25

Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities

Victor Floc'h

Exane BNP Paribas

2,650 p

Buy

70.53%

Upside

Initiated

05/14/25

BNP Paribas Exane Starts Hikma Pharmaceuticals Plc (HIK:LN) (HKMPF) at OutperformBNP Paribas Exane analyst Victor Floch initiates coverage on Hikma Pharmaceuticals Plc (HIK:LN) (OTC: HKMPF) with a Outperform rating and a price target of GBP26.50.

Christian Glennie

Stifel Nicolaus

2,650 p

Buy

70.53%

Upside

Reiterated

04/24/25

Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Beatrice Fairbairn

Berenberg Bank

1,800 p→2,300 p

Buy

48.01%

Upside

Assigned

03/04/26

Berenberg Bank Remains a Buy on Hikma Pharmaceuticals (HIK)

Zain Ebrahim

J.P. Morgan

2,000 p

Buy

28.70%

Upside

Reiterated

03/03/26

Hikma Pharmaceuticals (HIK) Receives a Buy from J.P. Morgan

James Gordon CFA

Barclays

1,350 p

Sell

-13.13%

Downside

Reiterated

03/02/26

Barclays Sticks to Their Sell Rating for Hikma Pharmaceuticals (HIK)

Kane Slutzkin

Deutsche Bank

2,500 p→2,400 p

Buy

54.44%

Upside

Reiterated

01/09/26

Deutsche Bank Remains a Buy on Hikma Pharmaceuticals (HIK)

James Vane

Jefferies

2,360 p

Buy

51.87%

Upside

Reiterated

11/07/25

Hikma Pharmaceuticals (HIK) Receives a Buy from Jefferies

Unknown Analyst

Peel Hunt

Not Ranked

Peel Hunt

2,170 p

Buy

39.64%

Upside

Reiterated

11/07/25

Peel Hunt Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)

Alistair Campbell

RBC Capital

2,625 p

Buy

68.92%

Upside

Reiterated

08/11/25

Hikma Pharmaceuticals (HIK) Gets a Buy from RBC Capital

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

2,380 p

Hold

53.15%

Upside

Initiated

06/09/25

Hikma Pharmaceuticals (HIK) Initiated with a Hold at Bank of America Securities

Victor Floc'h

Exane BNP Paribas

2,650 p

Buy

70.53%

Upside

Initiated

05/14/25

Christian Glennie

Stifel Nicolaus

2,650 p

Buy

70.53%

Upside

Reiterated

04/24/25

Promising Financial Outlook and Strategic Positioning of Hikma Pharmaceuticals: A Buy Recommendation by Christian Glennie

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hikma Pharmaceuticals

3 Months

xxx

Success Rate

3/7 ratings generated profit

Average Return

+2.77%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +2.77% per trade.

1 Year

James VaneJefferies

Success Rate

4/14 ratings generated profit

Average Return

-11.38%

reiterated a buy rating 4 months ago

Copying James Vane's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -11.38% per trade.

2 Years

xxx

Success Rate

4/14 ratings generated profit

Average Return

-8.26%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -8.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIK Analyst Recommendation Trends

Rating

Aug 25

Oct 25

Nov 25

Jan 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HIK has received 8 Buy Ratings, 1 Hold Ratings, and 2 Sell Ratings. HIK average Analyst price target in the past 3 months is 2,012.50.

Each month's total comprises the sum of three months' worth of ratings.

HIK Financial Forecast

HIK Earnings Forecast

The previous quarter’s earnings for HIK were 0.56 p.

HIK Sales Forecast

The previous quarter’s earnings for HIK were 1.26B .

HIK Stock Forecast FAQ

What is GB:HIK’s average 12-month price target, according to analysts?

Based on analyst ratings, Hikma Pharmaceuticals PLC’s 12-month average price target is 2,012.50.

What is GB:HIK’s upside potential, based on the analysts’ average price target?

Hikma Pharmaceuticals PLC has 29.50% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Hikma Pharmaceuticals PLC a Buy, Sell or Hold?

Hikma Pharmaceuticals PLC has a consensus rating of Moderate Buy, which is based on 3 buy ratings, 0 hold ratings and 1 sell ratings.

What is Hikma Pharmaceuticals PLC’s share price target?

The average share price target for Hikma Pharmaceuticals PLC is 2,012.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 2,400.00 p ,and the lowest forecast is 1,350.00 p. The average share price target represents 29.50% Increase from the current price of 1,554 p.

What do analysts say about Hikma Pharmaceuticals PLC?

Hikma Pharmaceuticals PLC’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of Hikma Pharmaceuticals PLC?

To buy shares of GB:HIK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Hikma Pharmaceuticals (HIK) Share Forecast & Price Target

HIK Analyst Ratings

HIK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hikma Pharmaceuticals

HIK Analyst Recommendation Trends

HIK Financial Forecast

HIK Earnings Forecast

HIK Sales Forecast

HIK Stock Forecast FAQ

Detailed List of Analyst Forecasts